Clinical Trial, Meta-Analysis Find Diabetes Drugs May Benefit All Heart Failure Patients
In a large-scale clinical trial, researchers from the Brigham found that dapagliflozin, an SGLT2 inhibitor, reduced the risk of cardiovascular death or worsening heart failure irrespective of ejection fraction; A meta-analysis also presented by Br
Source: BWH News - Category: Hospital Management Source Type: news
More News: Cardiology | Cardiovascular | Clinical Trials | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Heart Failure | Hospital Management | SGLT2 Inhibitors